Act Before 11:59pm: Last Day to SAVE 80% on Our Midcap Stocks Research
Here is the latest financial fact sheet of NURECA. For more details, see the NURECA quarterly results and NURECA share price. For a sector overview, read our pharmaceuticals sector report.
1 Day | % | 1.3 |
No. of shares | m | 10.00 |
1 Week | % | 5.1 |
1 Month | % | -0.6 |
1 Year | % | -11.5 |
52 week H/L | Rs | 468.3/252.4 |
No. of Mths Year Ending |
12 Mar-19* |
12 Mar-20* |
12 Mar-21* |
12 Mar-22* |
12 Mar-23* |
5-Yr Chart Click to enlarge
|
---|
NURECA EQUITY SHARE DATA | |||||||
---|---|---|---|---|---|---|---|
High | Rs | NA | NA | 760 | 2,317 | 1,448 | |
Low | Rs | NA | NA | 559 | 589 | 294 | |
Sales per share (Unadj.) | Rs | 61,897.0 | 99,426.0 | 213.5 | 255.5 | 111.3 | |
Earnings per share (Unadj.) | Rs | 6,226.0 | 6,395.0 | 46.4 | 45.0 | -8.3 | |
Diluted earnings per share | Rs | 6.2 | 6.4 | 46.4 | 45.0 | -8.2 | |
Cash flow per share (Unadj.) | Rs | 6,283.0 | 6,769.0 | 46.8 | 46.4 | -5.9 | |
Dividends per share (Unadj.) | Rs | 0 | 0 | 2.00 | 3.00 | 0 | |
Adj. dividends per share | Rs | 0.00 | 0.00 | 2.00 | 3.00 | 0.00 | |
Avg Dividend yield | % | 0 | 0 | 0.3 | 0.2 | 0 | |
Book value per share (Unadj.) | Rs | 6,955.0 | 13,935.0 | 163.1 | 203.2 | 194.9 | |
Adj. book value per share | Rs | 7.0 | 13.9 | 163.1 | 203.2 | 194.9 | |
Shares outstanding (eoy) | m | 0.01 | 0.01 | 10.00 | 10.00 | 10.00 | |
Price / Sales ratio | x | 0 | 0 | 3.1 | 5.7 | 7.8 | |
Avg P/E ratio | x | 0 | 0 | 14.2 | 32.3 | -105.6 | |
P/CF ratio (eoy) | x | 0 | 0 | 14.1 | 31.3 | -148.6 | |
Price / Book Value ratio | x | 0 | 0 | 4.0 | 7.1 | 4.5 | |
Dividend payout | % | 0 | 0 | 4.3 | 6.7 | 0 | |
Avg Mkt Cap | Rs m | 0 | 0 | 6,596 | 14,526 | 8,710 | |
Total wages/salary | Rs m | 9 | 32 | 46 | 99 | 161 |
NURECA INCOME DATA | |||||||
---|---|---|---|---|---|---|---|
Net Sales | Rs m | 619 | 994 | 2,135 | 2,555 | 1,113 | |
Other income | Rs m | 1 | 1 | 28 | 77 | 71 | |
Total revenues | Rs m | 620 | 995 | 2,163 | 2,632 | 1,184 | |
Gross profit | Rs m | 91 | 97 | 615 | 555 | -150 | |
Depreciation | Rs m | 1 | 4 | 4 | 15 | 24 | |
Interest | Rs m | 2 | 8 | 16 | 7 | 5 | |
Profit before tax | Rs m | 88 | 86 | 623 | 610 | -107 | |
Minority Interest | Rs m | 0 | 0 | 0 | 0 | 0 | |
Prior Period Items | Rs m | 0 | 0 | 0 | 0 | 0 | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Tax | Rs m | 26 | 22 | 160 | 160 | -25 | |
Profit after tax | Rs m | 62 | 64 | 464 | 450 | -83 | |
Gross profit margin | % | 14.6 | 9.7 | 28.8 | 21.7 | -13.5 | |
Effective tax rate | % | 29.6 | 25.7 | 25.6 | 26.3 | 23.2 | |
Net profit margin | % | 10.1 | 6.4 | 21.7 | 17.6 | -7.4 |
NURECA BALANCE SHEET DATA | |||||||
---|---|---|---|---|---|---|---|
Current assets | Rs m | 230 | 328 | 1,862 | 2,392 | 1,866 | |
Current liabilities | Rs m | 153 | 95 | 239 | 453 | 89 | |
Net working cap to sales | % | 12.4 | 23.4 | 76.0 | 75.9 | 159.6 | |
Current ratio | x | 1.5 | 3.4 | 7.8 | 5.3 | 20.9 | |
Inventory Days | Days | 0 | 0 | 0 | 51 | 222 | |
Debtors Days | Days | 52 | 47 | 0 | 4 | 14 | |
Net fixed assets | Rs m | 5 | 11 | 41 | 128 | 173 | |
Share capital | Rs m | 0 | 0 | 100 | 100 | 100 | |
"Free" reserves | Rs m | 69 | 139 | 1,531 | 1,932 | 1,849 | |
Net worth | Rs m | 70 | 139 | 1,631 | 2,032 | 1,949 | |
Long term debt | Rs m | 3 | 93 | 8 | 0 | 0 | |
Total assets | Rs m | 235 | 338 | 1,903 | 2,521 | 2,039 | |
Interest coverage | x | 37.4 | 12.1 | 39.9 | 83.3 | -22.9 | |
Debt to equity ratio | x | 0 | 0.7 | 0 | 0 | 0 | |
Sales to assets ratio | x | 2.6 | 2.9 | 1.1 | 1.0 | 0.5 | |
Return on assets | % | 27.5 | 21.2 | 25.2 | 18.1 | -3.8 | |
Return on equity | % | 89.5 | 45.9 | 28.4 | 22.1 | -4.2 | |
Return on capital | % | 125.9 | 40.3 | 39.0 | 30.4 | -5.3 | |
Exports to sales | % | 0 | 0 | 0 | 0 | 0 | |
Imports to sales | % | 0 | 0 | 0 | 0 | 0 | |
Exports (fob) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Imports (cif) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Fx inflow | Rs m | 0 | 0 | 0 | 0 | 0 | |
Fx outflow | Rs m | 0 | 0 | 0 | 1,160 | 230 | |
Net fx | Rs m | 0 | 0 | 0 | -1,160 | -230 |
NURECA CASH FLOW | |||||||
---|---|---|---|---|---|---|---|
From Operations | Rs m | 3 | -79 | 349 | 14 | 102 | |
From Investments | Rs m | -1 | -4 | -1,100 | -31 | -165 | |
From Financial Activity | Rs m | -1 | 83 | 923 | -73 | -15 | |
Net Cashflow | Rs m | 0 | -0 | 172 | -90 | -77 |
Share Holding
Shareholding as on Mar 2024
|
Company Information
|
CHM: Saurabh Goyal | COMP SEC: Chetna Anand | YEAR OF INC: 2016 | BSE CODE: 543264 | FV (Rs): 10 | DIV YIELD (%): - |
Read: NURECA 2022-23 Annual Report Analysis
More Medical Equipment/supplies/accessories Company Fact Sheets: DIVIS LABORATORIES DR. REDDYS LAB ZYDUS LIFESCIENCES CIPLA SUN PHARMA
Compare NURECA With: DIVIS LABORATORIES DR. REDDYS LAB ZYDUS LIFESCIENCES CIPLA SUN PHARMA
After opening the day on high, Indian share markets continued the momentum as the session progressed and ended the higher.